TY - JOUR
TI - Histone deacetylase inhibitors and papillary thyroid cancer
AU - Spartalis, E.
AU - Kotrotsios, K.
AU - Chrysikos, D.
AU - Spartalis, M.
AU - Paschou, S.A.
AU - Schizas, D.
AU - Tsamakis, K.
AU - Dimitroulis, D.
AU - Troupis, T.
AU - Nikiteas, N.
JO - Current Pharmaceutical Design
PY - 2021
VL - 27
TODO - 18
SP - 2199-2208
PB - Bentham Science Publishers
SN - 1381-6128
TODO - 10.2174/1381612826666201211112234
TODO - belinostat;  butyric acid;  fimepinostat;  histone deacetylase inhibitor;  hydroxamic acid derivative;  n hydroxy 7 (2 naphthylthio) hepanomide;  panobinostat;  romidepsin;  suberoyl anilide hydroxamic acid;  trichostatin A;  unclassified drug;  valproic acid;  histone;  histone deacetylase inhibitor;  hydroxamic acid;  panobinostat, antineoplastic activity;  clinical research;  clinical trial (topic);  drug response;  drug structure;  human;  monotherapy;  nonhuman;  Review;  thyroid papillary carcinoma;  thyroid papillary carcinoma cell line;  trend study;  thyroid tumor, Histone Deacetylase Inhibitors;  Histones;  Humans;  Hydroxamic Acids;  Panobinostat;  Thyroid Cancer, Papillary;  Thyroid Neoplasms
TODO - Background/Aim: Papillary Thyroid Cancer (PTC) is the most common type of endocrine malignan-cy. Although PTC has an excellent prognosis, the recurrent or metastatic disease could affect patients' survival. Recent studies show that Histone Deacetylase Inhibitors (HDACIs) might be promising anticancer agents against PTC. The aim of this review is to evaluate the role of HDACIs as an additional modality in PTC treatment and to depict the latest trends of current research on this field. Materials and Methods: This literature review was performed using the MEDLINE database. The search strategy included terms: “thyroid cancer”, “papillary”, “HDAC”, “histone”, and “deacetylase”. Results: Agents, such as Suberoyl Anilide Hydroxamic Acid, Trichostatin A, Valproic Acid, Sodium butyrate, Panobinostat, Belinostat, Romidepsin, CUDC907 and N-Hydroxy-7-(2-naphthylthio)-Hepanomide have shown promising anti-cancer effects on PTC cell lines but fail to trigger a major response in clinical trials. Conclusion: HDACIs have no significant effect as monotherapy against PTC, but further research needs to be conducted in order to investigate their potential effect when used as an additional modality. © 2021 Bentham Science Publishers.
ER -